Abstract
OBJECTIVE: This study aims to evaluate the efficacy of Montelukast Sodium in combination with Erythromycin Cyclocarbonate for the treatment of children with Mycoplasma Pneumoniae infection, as well as their effects on the improvements of lung function, serum stress indicators, and antioxidant capacity indicators. METHODS: A retrospective analysis was conducted on 188 children with Mycoplasma Pneumoniae infection treated in Dujiangyan Shoujia Hospital from April 2023 to April 2024. The 188 children were divided into the research group (n=94) and the control group (n=94) according the treatment they received, with children in the research group receiving a combination of Erythromycin Cyclocarbonate and Montelukast Sodium tablets, while those in the control group receiving Erythromycin Cyclocarbonate only. The therapeutic efficacy, pulmonary function, symptom alleviation time, serum stress indicator levels, antioxidant capacity indicators, and serum IgA and IgM levels of participants were statistically analyzed and compared between the two groups. RESULTS: In comparison to the control group, the research group demonstrated better clinical efficacy, shorter time for the clinical symptoms to disappear, significant improvement in pulmonary function indicators, markedly decreased serum stress indicators (P < 0.05), significantly increased serum IgA and IgM levels (P < 0.05), as well as notably improved antioxidant capacity indicators (P < 0.05). CONCLUSION: Montelukast Sodium in combination with Erythromycin Cyclocarbonate treatment regimen increases the efficacy in treating Mycoplasma Pneumoniae infection in children compared to the use of Erythromycin Cyclocarbonate alone. This combination therapy can alleviate clinical symptoms faster, improve pulmonary function, reduce serum stress indicators, reduce the occurrence of adverse events, and enhance immune function in children with Mycoplasma Pneumoniae infection post treatment.